Rosetta Genomics sales and marketing update

Rosetta launched two fibroblast growth factor (FGF) receptor 3 ( FGFR3; CD333) gene mutation assays. The first detects the recurrence of FGFR3-positive low-grade bladder cancer from urine. The secon...